Comparing the values of anti-TPO and IL-17 among patients with thyroid disorders and comparing them with healthy controls in Ramadi City
Keywords:
IL-17, thyroid, healthy controlsAbstract
Even though most thyroid subjects are undiagnosed due to nonspecific symptoms, universal screening for thyroid disease is not recommended for the general population. In this study, our motive is to compare thyroid autoantibody anti-TPO and IL-17 in addition to traditional thyroid markers TSH, T4, and T3 between two patients' groups (patients with hypothyroidism (TSH) > 6 mIU/L and patients with hyperthyroidism TSH between 0.3 and 6 mIU/L) with a control group. Here a total of 45 subjects were divided into three groups, the first group consisted of 15 patients with hyperthyroidism. The second group consisted of 15 individuals with hypothyroidism, and the control group consisted of 15 healthy individuals. According to our results, an increase in TPO values was observed in all study groups, and the highest increase was recorded in the hyperthyroidism (386.672±116.924), and with regard to interleukin-17 values, a high value was observed in patients with hyperthyroidism (38.1033±5.44) compared to other groups.
Downloads
References
M. Mohamedali, S. R. Maddika, A. Vyas, V. Iyer, and P. Cheriyath. (2014). “Thyroid disorders and chronic kidney disease,” International Journal of Nephrology, vol. 2014, Article ID520281.
J. G. Hollowell, N. W. Staehling, W. D. Flanders. (2002). “Serum TSH, T4, and thyroid antibodies in the united states population (1988 to 1994): National health and nutrition examination survey (NHANES III),” The Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 2, pp. 489–499.
Siriwardhane, T., Krishna, K., Ranganathan, V., Jayaraman, V., Wang, T., Bei, K., & Krishnamurthy, H. (2019). Significance of anti-TPO as an early predictive marker in thyroid disease. Autoimmune diseases, 2019:4-6.
Li, J., Sun, X., Yao, D., & Xia, J. (2018). Elevated serum IL-17 expression at cessation associated with Graves’ disease relapse. International journal of endocrinology, 2018.
S. De Leo, S. Y. Lee, and L. E. Braverman. (2016). Hyperthyroidism. Lancet, vol. 388, no. 10047, pp. 906–918.
G. A. Brent. (2008) “Clinical practice. Graves’ disease,” The New England Journal of Medicine, vol. 358, no. 24, pp. 2594–2605.
Antonelli, A., Ferrari SM., Corrado , A. , Di Domenicantonio , A. Fallahi ,P. (2015) Autoimmune thyroid disorders. Autoimmun; 14:174‑80.
Hiromatsu Y, Satoh H, Amino N. (2013) . Hashimoto’s thyroiditis: history and future outlook. Hormones 12:12–8.
D. Leslie, P. Lipsky, and A. L. Notkins.( 2001). Autoantibodies as predictors of disease.The Journal of Clinical Investigation, vol.108, no. 10, pp. 1417–1422.
Le Fourn V, Ferrand M, Franc JL. (2005). Endoproteolytic cleavage of human thyro-peroxidase: role of the propeptide in the protein folding process. J Biol Chem 280:4568–77.
I. K. Macdonald, C. B. Parsy-Kowalska, and C. J. Chapman. (2017). Autoantibodies: opportunities for early cancer detection. Trends in Cancer, 3(3) pp. 198–213.
L. R. Ingle. (2008). Autoantibodies in celiac disease. Autoimmunity, 41(5) : 340.
Balucan FS, Morshed SA, Davies TF. (2013). Thyroid autoantibodies in pregnancy: their role, regulation and clinical relevance. J Thyroid Res 2013:182472.
Ruggeri RM, Vicchio TM, Cristani M, Certo R, Caccamo D, Alibrandi A, et al. (2016). Oxidative stress and advanced glycation end products in Hashimoto’s thyroiditis. Thyroid 26:504–11.
. Zaletel K, Gaberscek S. (2011). Hashimoto’s thyroiditis: from genes to the disease. Curr Genomics 12:576–88.
J. K. Kolls and A. Linden. (2004). Interleukin-17 family members and inflammation. Immunity, vol. 21, no. 4, pp. 467–476.
T. Nanba, M. Watanabe, N. Inoue, and Y. Iwatani. (2009). Increases of the Th1/Th2 cell ratio in severe Hashimoto’s disease and in the proportion of Th17 cells in intractable Graves’ disease. Thyroid, 19(5) :495–501.
Figueroa-Vega N, Alfonso-Pe´rez M, Benedicto I et al (2010). Increased circulating pro-inflammatory cytokines and Th17 lymphocytes in Hashimoto’s thyroiditis. J Clin Endocrinol Metab 95:953–962.
Kim J, Kang S, Kim J et al. (2013). Elevated levels of T helper 17 cells are associated with disease activity in patients with rheumatoid arthritis. Ann Lab. Med. 33:52–59.
Diani M, Altomare G, Reali E. (2016). T helper cell subsets in clinical manifestations of psoriasis. J Immunol Res; 2016:7692024.
Beringer A, Noack M, Miossec P. (2016). IL‑17 in chronic inflammation: From discovery to targeting. Trends Mol Med; 22:230‑41.
Li D, Cai W, Gu R, Zhang Y, Zhang H, Tang K, et al. (2013).Th-17 cell plays a role in the pathogenesis of Hashimoto’s thyroiditis in patients. Clin Immunol;149:411‑20.
Horie I, Abiru N, Nagayama Y, Kuriya G, Saitoh O, Ichikawa T, et al.(2009). T helper type 17 immune response plays an indispensable role for development of iodine‑induced autoimmune thyroiditis in nonobese diabetic‑H2h4 mice. Endocrinology;150:5135‑42.
M. W. Al-Rabi.( 2017) .Correlation of thyroid antibodies with TSH, T3 and T4 hormones in patients diagnosed with autoimmune thyroid disorders. Pakistan Journal of Pharmaceutical Sciences, vol. 30, 2, 607–612.
S. J. Brown, A. P. Bremner, N. C. Hadlow et al. (2016). The log TSH– free T4 relationship in a community-based cohort is nonlinear and is influenced by age, smoking and thyroid peroxidase antibody status. Clinical Endocrinology, vol. 85,5. 789–796.
S. M. Ghoraishian, S. H. Hekmati Moghaddam, and M. Afkhami-Ardekani. (2006) .Relationship between anti-thyroid peroxidase antibody and thyroid function test. Iranian Journal of Immunology, vol. 3. 13. 146–149.
Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Health and treatment of diabetes mellitus. International Journal of Health Sciences, 5(1), i-v. https://doi.org/10.53730/ijhs.v5n1.2864
Widana, I.K., Sumetri, N.W., Sutapa, I.K., Suryasa, W. (2021). Anthropometric measures for better cardiovascular and musculoskeletal health. Computer Applications in Engineering Education, 29(3), 550–561. https://doi.org/10.1002/cae.22202
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
